康哲药业(00867)获得1类新药MG-K10人源化单抗注射液新增慢性阻塞性肺疾病适应症药物临床试验批准通知书

智通财经09-30

智通财经APP讯，康哲药业(00867)公布，集团拥有共同开发权(除特应性皮炎(AD)外)及独家商业化权利的1类新药抗IL-4Rα MG-K10人源化单抗注射液(MG-K10)于2025年9月29日获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书， NMPA同意开展MG-K10用于慢性阻塞性肺疾病(COPD)的临床试验。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2571347026?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-30 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571347026","market":"fut","top_or_hot":-1,"title":"康哲药业(00867)获得1类新药MG-K10人源化单抗注射液新增慢性阻塞性肺疾病适应症药物临床试验批准通知书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康哲药业(00867)公布，集团拥有共同开发权(除特应性皮炎(AD)外)及独家商业化权利的1类新药抗IL-4Rα MG-K10人源化单抗注射液(MG-K10)于2025年9月29日获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书， NMPA同意开展MG-K10用于慢性阻塞性肺疾病(COPD)的临床试验。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1351489.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业(00867)获得1类新药MG-K10人源化单抗注射液新增慢性阻塞性肺疾病适应症药物临床试验批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业(00867)获得1类新药MG-K10人源化单抗注射液新增慢性阻塞性肺疾病适应症药物临床试验批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-30 20:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1351489.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康哲药业(00867)公布，集团拥有共同开发权(除特应性皮炎(AD)外)及独家商业化权利的1类新药抗IL-4Rα MG-K10人源化单抗注射液(MG-K10)于2025年9月29日获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书， NMPA同意开展MG-K10用于慢性阻塞性肺疾病(COPD)的临床试验。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1351489.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00867","symbol_name":"康哲药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1351489.html","article_id":"2571347026","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571347026","pubTimestamp":1759235825,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康哲药业(00867)公布，集团拥有共同开发权(除特应性皮炎(AD)外)及独家商业化权利的1类新药抗IL-4Rα MG-K10人源化单抗注射液(MG-K10)于2025年9月29日获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书， NMPA同意开展MG-K10用于慢性阻塞性肺疾病(COPD)的临床试验。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00867":"康哲药业","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","BK4123":"调查和咨询服务","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","MG":"Mistras Group","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1191":"制药","BK1593":"医美概念股","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC"},"translate_title":"Kangzhe Pharmaceutical (00867) obtained the approval notice for clinical trials of Class 1 new drug MG-K10 humanized monoclonal antibody injection for new chronic obstructive pulmonary disease indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MG":1.5,"00867":1.5},"content_text":"智通财经APP讯，康哲药业(00867)公布，集团拥有共同开发权(除特应性皮炎(AD)外)及独家商业化权利的1类新药抗IL-4Rα MG-K10人源化单抗注射液(MG-K10)于2025年9月29日获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书， NMPA同意开展MG-K10用于慢性阻塞性肺疾病(COPD)的临床试验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571347026","isCrawlerRequest":true}